APO Research
Talk to an analyst

APO RESEARCH · REPORT

DNA Damage Response Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global DNA Damage Response Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025196 pages

Choose your research edition.

Industry ResearchDNA Damage Response Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal DNA Damage Response Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal DNA Damage Response Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DNA Damage Response Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal DNA Damage Response Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global DNA Damage Response Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for DNA Damage Response Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DNA Damage Response Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DNA Damage Response Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for DNA Damage Response Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of DNA Damage Response Drugs include Merck, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Zentalis Pharmaceuticals, Sierra Oncology, Repare Therapeutics and Onxeo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global DNA Damage Response Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DNA Damage Response Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DNA Damage Response Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the DNA Damage Response Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

DNA Damage Response Drugs Segment by Company

Merck

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Zentalis Pharmaceuticals

Sierra Oncology

Repare Therapeutics

Onxeo

NMS Group SpA

Eli Lilly and Company

Debiopharm

Clovis Oncology

BeiGene

AbbVie Inc

DNA Damage Response Drugs Segment by Type

Lynparza

Rubraca

Talzenna

Zejula

DNA Damage Response Drugs Segment by Application

Pancreatic Cancer

Breast Cancer

Prostate Cancer

Ovarian Cancer

DNA Damage Response Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA Damage Response Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DNA Damage Response Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA Damage Response Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of DNA Damage Response Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DNA Damage Response Drugs industry.

Chapter 3: Detailed analysis of DNA Damage Response Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, DNA Damage Response Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global DNA Damage Response Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Lynparza Table 3. Key Players of Rubraca Table 4. Key Players of Talzenna Table 3. Key Players of Zejula Table 4. Global DNA Damage Response Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Pancreatic Cancer Table 6. Key Players of Breast Cancer Table 7. Key Players of Prostate Cancer Table 8. Key Players of Ovarian Cancer Table 9. Global DNA Damage Response Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global DNA Damage Response Drugs Market Size by Region (2021-2026) & (US$ Million) Table 11. Global DNA Damage Response Drugs Market Share by Region (2021-2026) Table 12. Global DNA Damage Response Drugs Market Size by Region (2027-2032) & (US$ Million) Table 13. Global DNA Damage Response Drugs Market Share by Region (2027-2032) Table 14. DNA Damage Response Drugs Industry Trends Table 15. DNA Damage Response Drugs Industry Drivers Table 16. DNA Damage Response Drugs Industry Opportunities and Challenges Table 17. DNA Damage Response Drugs Industry Restraints Table 18. Global DNA Damage Response Drugs Revenue by Company (US$ Million) & (2021-2026) Table 19. Global DNA Damage Response Drugs Revenue Market Share by Company (2021-2026) Table 20. Global DNA Damage Response Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global DNA Damage Response Drugs Key Company Head Office and Area Served Table 22. Global DNA Damage Response Drugs Company, Product Type & Application Table 23. Global DNA Damage Response Drugs Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global DNA Damage Response Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global DNA Damage Response Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global DNA Damage Response Drugs Market Size by Type (2021-2026) & (US$ Million) Table 28. Global DNA Damage Response Drugs Market Size by Type (2027-2032) & (US$ Million) Table 29. Global DNA Damage Response Drugs Revenue Market Share by Type (2021-2026) Table 30. Global DNA Damage Response Drugs Revenue Market Share by Type (2027-2032) Table 31. Global DNA Damage Response Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global DNA Damage Response Drugs Market Size by Application (2021-2026) & (US$ Million) Table 33. Global DNA Damage Response Drugs Market Size by Application (2027-2032) & (US$ Million) Table 34. Global DNA Damage Response Drugs Revenue Market Share by Application (2021-2026) Table 35. Global DNA Damage Response Drugs Revenue Market Share by Application (2027-2032) Table 36. Merck Company Information Table 37. Merck Business Overview Table 38. Merck DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Merck DNA Damage Response Drugs Product Portfolio Table 40. Merck Recent Development Table 41. Pfizer Company Information Table 42. Pfizer Business Overview Table 43. Pfizer DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Pfizer DNA Damage Response Drugs Product Portfolio Table 45. Pfizer Recent Development Table 46. GlaxoSmithKline Company Information Table 47. GlaxoSmithKline Business Overview Table 48. GlaxoSmithKline DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GlaxoSmithKline DNA Damage Response Drugs Product Portfolio Table 50. GlaxoSmithKline Recent Development Table 51. Bayer Company Information Table 52. Bayer Business Overview Table 53. Bayer DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bayer DNA Damage Response Drugs Product Portfolio Table 55. Bayer Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca DNA Damage Response Drugs Product Portfolio Table 60. AstraZeneca Recent Development Table 61. Zentalis Pharmaceuticals Company Information Table 62. Zentalis Pharmaceuticals Business Overview Table 63. Zentalis Pharmaceuticals DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Zentalis Pharmaceuticals DNA Damage Response Drugs Product Portfolio Table 65. Zentalis Pharmaceuticals Recent Development Table 66. Sierra Oncology Company Information Table 67. Sierra Oncology Business Overview Table 68. Sierra Oncology DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sierra Oncology DNA Damage Response Drugs Product Portfolio Table 70. Sierra Oncology Recent Development Table 71. Repare Therapeutics Company Information Table 72. Repare Therapeutics Business Overview Table 73. Repare Therapeutics DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Repare Therapeutics DNA Damage Response Drugs Product Portfolio Table 75. Repare Therapeutics Recent Development Table 76. Onxeo Company Information Table 77. Onxeo Business Overview Table 78. Onxeo DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Onxeo DNA Damage Response Drugs Product Portfolio Table 80. Onxeo Recent Development Table 81. NMS Group SpA Company Information Table 82. NMS Group SpA Business Overview Table 83. NMS Group SpA DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. NMS Group SpA DNA Damage Response Drugs Product Portfolio Table 85. NMS Group SpA Recent Development Table 86. Eli Lilly and Company Company Information Table 87. Eli Lilly and Company Business Overview Table 88. Eli Lilly and Company DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Eli Lilly and Company DNA Damage Response Drugs Product Portfolio Table 90. Eli Lilly and Company Recent Development Table 91. Debiopharm Company Information Table 92. Debiopharm Business Overview Table 93. Debiopharm DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Debiopharm DNA Damage Response Drugs Product Portfolio Table 95. Debiopharm Recent Development Table 96. Clovis Oncology Company Information Table 97. Clovis Oncology Business Overview Table 98. Clovis Oncology DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Clovis Oncology DNA Damage Response Drugs Product Portfolio Table 100. Clovis Oncology Recent Development Table 101. BeiGene Company Information Table 102. BeiGene Business Overview Table 103. BeiGene DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. BeiGene DNA Damage Response Drugs Product Portfolio Table 105. BeiGene Recent Development Table 106. AbbVie Inc Company Information Table 107. AbbVie Inc Business Overview Table 108. AbbVie Inc DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. AbbVie Inc DNA Damage Response Drugs Product Portfolio Table 110. AbbVie Inc Recent Development Table 111. North America DNA Damage Response Drugs Market Size by Type (2021-2026) & (US$ Million) Table 112. North America DNA Damage Response Drugs Market Size by Type (2027-2032) & (US$ Million) Table 113. North America DNA Damage Response Drugs Market Size by Application (2021-2026) & (US$ Million) Table 114. North America DNA Damage Response Drugs Market Size by Application (2027-2032) & (US$ Million) Table 115. North America DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America DNA Damage Response Drugs Market Size by Country (2021-2026) Table 117. North America DNA Damage Response Drugs Market Size by Country (2027-2032) Table 118. Europe DNA Damage Response Drugs Market Size by Type (2021-2026) & (US$ Million) Table 119. Europe DNA Damage Response Drugs Market Size by Type (2027-2032) & (US$ Million) Table 120. Europe DNA Damage Response Drugs Market Size by Application (2021-2026) & (US$ Million) Table 121. Europe DNA Damage Response Drugs Market Size by Application (2027-2032) & (US$ Million) Table 122. Europe DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe DNA Damage Response Drugs Market Size by Country (2021-2026) Table 124. Europe DNA Damage Response Drugs Market Size by Country (2027-2032) Table 125. China DNA Damage Response Drugs Market Size by Type (2021-2026) & (US$ Million) Table 126. China DNA Damage Response Drugs Market Size by Type (2027-2032) & (US$ Million) Table 127. China DNA Damage Response Drugs Market Size by Application (2021-2026) & (US$ Million) Table 128. China DNA Damage Response Drugs Market Size by Application (2027-2032) & (US$ Million) Table 129. Asia DNA Damage Response Drugs Market Size by Type (2021-2026) & (US$ Million) Table 130. Asia DNA Damage Response Drugs Market Size by Type (2027-2032) & (US$ Million) Table 131. Asia DNA Damage Response Drugs Market Size by Application (2021-2026) & (US$ Million) Table 132. Asia DNA Damage Response Drugs Market Size by Application (2027-2032) & (US$ Million) Table 133. Asia DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia DNA Damage Response Drugs Market Size by Country (2021-2026) Table 135. Asia DNA Damage Response Drugs Market Size by Country (2027-2032) Table 136. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Type (2021-2026) & (US$ Million) Table 137. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Type (2027-2032) & (US$ Million) Table 138. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Application (2021-2026) & (US$ Million) Table 139. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Application (2027-2032) & (US$ Million) Table 140. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country (2021-2026) Table 142. South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. DNA Damage Response Drugs Product Image Figure 2. Global DNA Damage Response Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global DNA Damage Response Drugs Market Share by Type: 2025 VS 2032 Figure 4. Lynparza Image Figure 5. Rubraca Image Figure 6. Talzenna Image Figure 7. Zejula Image Figure 8. Global DNA Damage Response Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global DNA Damage Response Drugs Market Share by Application: 2025 VS 2032 Figure 10. Pancreatic Cancer Image Figure 11. Breast Cancer Image Figure 12. Prostate Cancer Image Figure 13. Ovarian Cancer Image Figure 14. Global DNA Damage Response Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 16. Global DNA Damage Response Drugs Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global DNA Damage Response Drugs Market Share by Players in 2025 Figure 19. Global Top 5 and 10 DNA Damage Response Drugs Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global DNA Damage Response Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global DNA Damage Response Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global DNA Damage Response Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global DNA Damage Response Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 26. North America DNA Damage Response Drugs Market Share by Type (2021-2032) Figure 27. North America DNA Damage Response Drugs Market Share by Application (2021-2032) Figure 28. North America DNA Damage Response Drugs Market Share by Country (2021-2032) Figure 29. United States DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Canada DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Mexico DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 32. Europe DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 33. Europe DNA Damage Response Drugs Market Share by Type (2021-2032) Figure 34. Europe DNA Damage Response Drugs Market Share by Application (2021-2032) Figure 35. Europe DNA Damage Response Drugs Market Share by Country (2021-2032) Figure 36. Germany DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 37. France DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 38. U.K. DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Italy DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 40. Russia DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 42. China DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 43. China DNA Damage Response Drugs Market Share by Type (2021-2032) Figure 44. China DNA Damage Response Drugs Market Share by Application (2021-2032) Figure 45. Asia DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 46. Asia DNA Damage Response Drugs Market Share by Type (2021-2032) Figure 47. Asia DNA Damage Response Drugs Market Share by Application (2021-2032) Figure 48. Asia DNA Damage Response Drugs Market Share by Country (2021-2032) Figure 49. Japan DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 50. South Korea DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 53. India DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 54. Australia DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa DNA Damage Response Drugs Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa DNA Damage Response Drugs Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa DNA Damage Response Drugs Market Share by Country (2021-2032) Figure 59. Brazil DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 60. South Africa DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 62. Turkey DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Argentina DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 64. UAE DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Egypt DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Chile DNA Damage Response Drugs Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Lynparza
  • Rubraca
  • Talzenna
  • Zejula
Applications
  • Pancreatic Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
Companies covered
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Zentalis Pharmaceuticals
  • Sierra Oncology
  • Repare Therapeutics
  • Onxeo
  • NMS Group SpA
  • Eli Lilly and Company
  • Debiopharm
  • Clovis Oncology
  • BeiGene
  • AbbVie Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global DNA Damage Response Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Lynparza
  5. 1.2.3 Rubraca
  6. 1.2.4 Talzenna
  7. 1.2.5 Zejula
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global DNA Damage Response Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Pancreatic Cancer
  11. 1.3.3 Breast Cancer
  12. 1.3.4 Prostate Cancer
  13. 1.3.5 Ovarian Cancer
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global DNA Damage Response Drugs Growth Trends by Region
  16. 1.5.1 Global DNA Damage Response Drugs Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 DNA Damage Response Drugs Market Size by Region (2021-2026)
  18. 1.5.3 DNA Damage Response Drugs Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global DNA Damage Response Drugs Market Dynamics
  1. 2.1 DNA Damage Response Drugs Industry Trends
  2. 2.2 DNA Damage Response Drugs Industry Drivers
  3. 2.3 DNA Damage Response Drugs Industry Opportunities and Challenges
  4. 2.4 DNA Damage Response Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global DNA Damage Response Drugs Revenue by Company (2021-2026)
  2. 3.2 Global DNA Damage Response Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global DNA Damage Response Drugs Key Company Head office and Area Served
  4. 3.4 Global DNA Damage Response Drugs Company, Product Type & Application
  5. 3.5 Global DNA Damage Response Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global DNA Damage Response Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 DNA Damage Response Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 DNA Damage Response Drugs Tier 1, Tier 2, and Tier 3
4 DNA Damage Response Drugs Market by Type
  1. 4.1 Global DNA Damage Response Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global DNA Damage Response Drugs Market Size by Type (2021-2032)
  3. 4.3 Global DNA Damage Response Drugs Market Size Share by Type (2021-2032)
5 DNA Damage Response Drugs Market by Application
  1. 5.1 Global DNA Damage Response Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global DNA Damage Response Drugs Market Size by Application (2021-2032)
  3. 5.3 Global DNA Damage Response Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Merck DNA Damage Response Drugs Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Pfizer DNA Damage Response Drugs Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 GlaxoSmithKline
  14. 6.3.1 GlaxoSmithKline Company Information
  15. 6.3.2 GlaxoSmithKline Business Overview
  16. 6.3.3 GlaxoSmithKline DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 GlaxoSmithKline DNA Damage Response Drugs Product Portfolio
  18. 6.3.5 GlaxoSmithKline Recent Developments
  19. 6.4 Bayer
  20. 6.4.1 Bayer Company Information
  21. 6.4.2 Bayer Business Overview
  22. 6.4.3 Bayer DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bayer DNA Damage Response Drugs Product Portfolio
  24. 6.4.5 Bayer Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AstraZeneca DNA Damage Response Drugs Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Zentalis Pharmaceuticals
  32. 6.6.1 Zentalis Pharmaceuticals Company Information
  33. 6.6.2 Zentalis Pharmaceuticals Business Overview
  34. 6.6.3 Zentalis Pharmaceuticals DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Zentalis Pharmaceuticals DNA Damage Response Drugs Product Portfolio
  36. 6.6.5 Zentalis Pharmaceuticals Recent Developments
  37. 6.7 Sierra Oncology
  38. 6.7.1 Sierra Oncology Company Information
  39. 6.7.2 Sierra Oncology Business Overview
  40. 6.7.3 Sierra Oncology DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Sierra Oncology DNA Damage Response Drugs Product Portfolio
  42. 6.7.5 Sierra Oncology Recent Developments
  43. 6.8 Repare Therapeutics
  44. 6.8.1 Repare Therapeutics Company Information
  45. 6.8.2 Repare Therapeutics Business Overview
  46. 6.8.3 Repare Therapeutics DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Repare Therapeutics DNA Damage Response Drugs Product Portfolio
  48. 6.8.5 Repare Therapeutics Recent Developments
  49. 6.9 Onxeo
  50. 6.9.1 Onxeo Company Information
  51. 6.9.2 Onxeo Business Overview
  52. 6.9.3 Onxeo DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Onxeo DNA Damage Response Drugs Product Portfolio
  54. 6.9.5 Onxeo Recent Developments
  55. 6.10 NMS Group SpA
  56. 6.10.1 NMS Group SpA Company Information
  57. 6.10.2 NMS Group SpA Business Overview
  58. 6.10.3 NMS Group SpA DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 NMS Group SpA DNA Damage Response Drugs Product Portfolio
  60. 6.10.5 NMS Group SpA Recent Developments
  61. 6.11 Eli Lilly and Company
  62. 6.11.1 Eli Lilly and Company Company Information
  63. 6.11.2 Eli Lilly and Company Business Overview
  64. 6.11.3 Eli Lilly and Company DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Eli Lilly and Company DNA Damage Response Drugs Product Portfolio
  66. 6.11.5 Eli Lilly and Company Recent Developments
  67. 6.12 Debiopharm
  68. 6.12.1 Debiopharm Company Information
  69. 6.12.2 Debiopharm Business Overview
  70. 6.12.3 Debiopharm DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Debiopharm DNA Damage Response Drugs Product Portfolio
  72. 6.12.5 Debiopharm Recent Developments
  73. 6.13 Clovis Oncology
  74. 6.13.1 Clovis Oncology Company Information
  75. 6.13.2 Clovis Oncology Business Overview
  76. 6.13.3 Clovis Oncology DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Clovis Oncology DNA Damage Response Drugs Product Portfolio
  78. 6.13.5 Clovis Oncology Recent Developments
  79. 6.14 BeiGene
  80. 6.14.1 BeiGene Company Information
  81. 6.14.2 BeiGene Business Overview
  82. 6.14.3 BeiGene DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 BeiGene DNA Damage Response Drugs Product Portfolio
  84. 6.14.5 BeiGene Recent Developments
  85. 6.15 AbbVie Inc
  86. 6.15.1 AbbVie Inc Company Information
  87. 6.15.2 AbbVie Inc Business Overview
  88. 6.15.3 AbbVie Inc DNA Damage Response Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 AbbVie Inc DNA Damage Response Drugs Product Portfolio
  90. 6.15.5 AbbVie Inc Recent Developments
7 North America
  1. 7.1 North America DNA Damage Response Drugs Market Size (2021-2032)
  2. 7.2 North America DNA Damage Response Drugs Market Size by Type
  3. 7.2.1 North America DNA Damage Response Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America DNA Damage Response Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America DNA Damage Response Drugs Market Share by Type (2021-2032)
  6. 7.3 North America DNA Damage Response Drugs Market Size by Application
  7. 7.3.1 North America DNA Damage Response Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America DNA Damage Response Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America DNA Damage Response Drugs Market Share by Application (2021-2032)
  10. 7.4 North America DNA Damage Response Drugs Market Size by Country
  11. 7.4.1 North America DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America DNA Damage Response Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America DNA Damage Response Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America DNA Damage Response Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe DNA Damage Response Drugs Market Size (2021-2032)
  2. 8.2 Europe DNA Damage Response Drugs Market Size by Type
  3. 8.2.1 Europe DNA Damage Response Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe DNA Damage Response Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe DNA Damage Response Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe DNA Damage Response Drugs Market Size by Application
  7. 8.3.1 Europe DNA Damage Response Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe DNA Damage Response Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe DNA Damage Response Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe DNA Damage Response Drugs Market Size by Country
  11. 8.4.1 Europe DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe DNA Damage Response Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe DNA Damage Response Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe DNA Damage Response Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China DNA Damage Response Drugs Market Size (2021-2032)
  2. 9.2 China DNA Damage Response Drugs Market Size by Type
  3. 9.2.1 China DNA Damage Response Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China DNA Damage Response Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China DNA Damage Response Drugs Market Share by Type (2021-2032)
  6. 9.3 China DNA Damage Response Drugs Market Size by Application
  7. 9.3.1 China DNA Damage Response Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China DNA Damage Response Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China DNA Damage Response Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia DNA Damage Response Drugs Market Size (2021-2032)
  2. 10.2 Asia DNA Damage Response Drugs Market Size by Type
  3. 10.2.1 Asia DNA Damage Response Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia DNA Damage Response Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia DNA Damage Response Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia DNA Damage Response Drugs Market Size by Application
  7. 10.3.1 Asia DNA Damage Response Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia DNA Damage Response Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia DNA Damage Response Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia DNA Damage Response Drugs Market Size by Country
  11. 10.4.1 Asia DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia DNA Damage Response Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia DNA Damage Response Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia DNA Damage Response Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa DNA Damage Response Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa DNA Damage Response Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa DNA Damage Response Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa DNA Damage Response Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa DNA Damage Response Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst